Institution identification

PURI

https://redirect.ema.europa.eu/resource/49756

Institution ID

49756

Institution full name and acronym

Real World Solutions, IQVIA

Institution countries

Netherlands
United Kingdom (Northern Ireland)

Type of institution

Other

Institution website

ENCePP partner

Yes
Institution description
IQVIA is a leading global provider of advanced analytics,technology solutions and clinical research services to the life sciences industry dedicated to creating intelligent connections that deliver unique innovations and actionable insights. As part of IQVIA,Real World Solutions (IQVIA RWS) specializes in provision of Real World Evidence (RWE) studies. IQVIA RWS works with biopharmaceutical companies,government and academic research organizations to define,demonstrate and communicate clinical,economic and humanistic 'real-world' treatment value to healthcare system stakeholders. Within its global breadth of services,IQVIA has significant expertise in pharmacovigilance and risk management,pharmacoepidemiology and health outcomes,and regulatory consulting. IQVIA RWS has conducted,analyzed and reported thousands of research projects spanning all key design types and size.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A drug utilisation study (DUS) of the use of oral fidaxomicin in the routine clinical setting (2819-CL- 2002) (Anemone)
Drug utilisation study of Intuniv® (guanfacine extended release) in European Countries – A prescriber survey (Intuniv survey study Europe)
Drug Utilisation Study of Intuniv® (guanfacine extended release) in European Countries, Study protocol I: Database study (Intuniv data base study Europe)
Evaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitretinoin, and isotretinoin): a European before-after drug utilization study (DUS) using secondary data
Long-Term Post-Marketing Observational Study of the Safety of Roflumilast
Multi-country non-interventional study on the effectiveness and safety of Empagliflozin in adult patients with type 2 diabetes in Europe and Asia
Non-Interventional Post-Authorisation Safety Study (NI-PASS) as an effectiveness check of an additional Risk Minimisation Measure (aRMM) (Direct Healthcare Professional Communication [DHPC]) for Bendamustine
Patient and Prescriber Survey: Effectiveness measures to investigate awareness, knowledge and adherence to the Risk Minimisation Measures (RMMs) of the Pregnancy Prevention Program (PPP) for Oral Retinoids (Acitretin, Alitretinoin, and Isotretinoin)
Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study 201038)